H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $145.00 price target on Corcept Therapeutics (NASDAQ: CORT).

The analyst commented: "On June 02, Corcept presented complete analysis of the ongoing Phase 3 study ROSELLA at the 2025 annual meeting of American Society of Clinical Oncology. Recall, the 381-patiet pivotal ROSELLA study is evaluating relacorilant in combination with nab-paclitaxel compared to nab-paclitaxel monotherapy as a therapy to treat platinum-resistant, recurrent ovarian cancer. The study met its primary endpoint of improved progression-free survival by blinded independent central review (BICR). The study showed that patients treated with the combination therapy experience a statistically significantly 30% (HR: 0.70; p=0.0076) reduction in risk of disease progression or death compared to the nab-paclitaxel monotherapy treated cohort. The combination arm experienced a mPFS of 6.5 months vs 5.5 months achieved by the nab-paclitaxel monotherapy cohort (Exhibit 1). We maintain our Buy rating on CORT and our 12-month price target of $145 per diluted share."

For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.

Shares of Corcept Therapeutics closed at $71.68 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• Aurora Spine settles patent dispute, secures $600K insider loan